IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Rating of “Buy” from Analysts

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a consensus rating of “Buy” from the seven analysts that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have covered the stock in the last year is $286.67.

A number of research firms have recently issued reports on IDXX. Bank of America set a $300.00 price objective on shares of IDEXX Laboratories and gave the stock a “buy” rating in a research report on Friday, June 21st. Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Canaccord Genuity reissued a “buy” rating and set a $285.00 price objective on shares of IDEXX Laboratories in a research report on Friday, August 2nd. Credit Suisse Group increased their price objective on shares of IDEXX Laboratories from $282.00 to $293.00 and gave the stock an “outperform” rating in a research report on Friday, August 16th. Finally, BidaskClub cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 26th.

IDXX traded down $0.45 during trading on Wednesday, reaching $280.96. 158,533 shares of the stock traded hands, compared to its average volume of 457,232. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 4.49. The stock has a market capitalization of $23.71 billion, a PE ratio of 65.95 and a beta of 0.84. The stock’s 50-day moving average is $279.50 and its 200 day moving average is $245.24. IDEXX Laboratories has a 12 month low of $176.11 and a 12 month high of $292.17.



IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, August 1st. The company reported $1.43 EPS for the quarter, beating the Zacks’ consensus estimate of $1.37 by $0.06. The business had revenue of $620.10 million for the quarter, compared to analysts’ expectations of $627.10 million. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 earnings per share. As a group, equities research analysts anticipate that IDEXX Laboratories will post 4.86 EPS for the current year.

In related news, Director Sophie V. Vandebroek sold 9,044 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $263.86, for a total value of $2,386,349.84. Following the transaction, the director now owns 12,116 shares of the company’s stock, valued at approximately $3,196,927.76. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Michael Lane sold 17,961 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $264.10, for a total transaction of $4,743,500.10. The disclosure for this sale can be found here. Insiders have sold a total of 75,905 shares of company stock worth $20,052,806 in the last three months. Insiders own 2.70% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Chicago Capital LLC increased its stake in IDEXX Laboratories by 1.1% in the 2nd quarter. Chicago Capital LLC now owns 113,341 shares of the company’s stock valued at $31,206,000 after buying an additional 1,240 shares during the last quarter. HCR Wealth Advisors purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $218,000. WINTON GROUP Ltd increased its stake in IDEXX Laboratories by 20.5% in the 2nd quarter. WINTON GROUP Ltd now owns 5,010 shares of the company’s stock valued at $1,379,000 after buying an additional 852 shares during the last quarter. Piedmont Investment Advisors Inc. increased its stake in IDEXX Laboratories by 1.9% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 7,633 shares of the company’s stock valued at $1,707,000 after buying an additional 144 shares during the last quarter. Finally, Swiss National Bank increased its stake in IDEXX Laboratories by 2.2% in the 1st quarter. Swiss National Bank now owns 287,800 shares of the company’s stock valued at $64,352,000 after buying an additional 6,100 shares during the last quarter. 87.10% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: What are catch-up contributions?

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.